264 related articles for article (PubMed ID: 38514585)
1. Future Perspectives of Pulmonary Arterial Hypertension: A Review of Novel Pipeline Treatments and Indications.
Novara ME; Di Martino E; Stephens B; Nayrouz M; Vitulo P; Carollo A; Provenzani A
Drugs R D; 2024 Mar; 24(1):13-28. PubMed ID: 38514585
[TBL] [Abstract][Full Text] [Related]
2. Overview of treprostinil sodium for the treatment of pulmonary arterial hypertension.
Budev MM; Minai OA; Arroliga AC
Drugs Today (Barc); 2004 Mar; 40(3):225-34. PubMed ID: 15148531
[TBL] [Abstract][Full Text] [Related]
3. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
4. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2021 Mar; 3(3):CD004434. PubMed ID: 33765691
[TBL] [Abstract][Full Text] [Related]
5. Phosphodiesterase 5 inhibitors for pulmonary hypertension.
Barnes H; Brown Z; Burns A; Williams T
Cochrane Database Syst Rev; 2019 Jan; 1(1):CD012621. PubMed ID: 30701543
[TBL] [Abstract][Full Text] [Related]
6. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J
Cochrane Database Syst Rev; 2006 Jul; (3):CD004434. PubMed ID: 16856046
[TBL] [Abstract][Full Text] [Related]
7. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
[TBL] [Abstract][Full Text] [Related]
8. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2009 Jul; (3):CD004434. PubMed ID: 19588356
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
[No Abstract] [Full Text] [Related]
10. Future perspectives in pulmonary arterial hypertension.
Simonneau G; Hoeper MM; McLaughlin V; Rubin L; Galiè N
Eur Respir Rev; 2016 Dec; 25(142):381-389. PubMed ID: 27903660
[TBL] [Abstract][Full Text] [Related]
11. New pharmacotherapy options for pulmonary arterial hypertension.
Perrin S; Chaumais MC; O'Connell C; Amar D; Savale L; Jaïs X; Montani D; Humbert M; Simonneau G; Sitbon O
Expert Opin Pharmacother; 2015; 16(14):2113-31. PubMed ID: 26290279
[TBL] [Abstract][Full Text] [Related]
12. Endothelin receptor antagonists for pulmonary arterial hypertension.
Liu C; Chen J; Gao Y; Deng B; Liu K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD004434. PubMed ID: 23450552
[TBL] [Abstract][Full Text] [Related]
13. Building the case for novel clinical trials in pulmonary arterial hypertension.
Ryan JJ; Rich JD; Maron BA
Circ Cardiovasc Qual Outcomes; 2015 Jan; 8(1):114-23. PubMed ID: 25604559
[No Abstract] [Full Text] [Related]
14. Advances in targeted therapy for pulmonary arterial hypertension in children.
Li L; Zhu X; Chen X; Gao J; Ding C; Zhang M; Ma S
Eur J Pediatr; 2023 May; 182(5):2067-2076. PubMed ID: 36527480
[TBL] [Abstract][Full Text] [Related]
15. Integrating Data From Randomized Controlled Trials and Observational Studies to Assess Survival in Rare Diseases.
Torbicki A; Bacchi M; Delcroix M; Farber HW; Ghofrani HA; Hennessy B; Jansa P; Mehta S; Perchenet L; Pulido T; Rosenberg D; Rubin LJ; Sastry BKS; Simonneau G; Sitbon O; Souza R; Wei LJ; Channick R; Benza R
Circ Cardiovasc Qual Outcomes; 2019 May; 12(5):e005095. PubMed ID: 31109190
[TBL] [Abstract][Full Text] [Related]
16. Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension.
Bhogal S; Mukherjee D; Banerjee S; Tan W; Paul TK
Curr Probl Cardiol; 2018 May; 43(5):191-216. PubMed ID: 29174585
[TBL] [Abstract][Full Text] [Related]
17. STRIDE 1: effects of the selective ET(A) receptor antagonist, sitaxsentan sodium, in a patient population with pulmonary arterial hypertension that meets traditional inclusion criteria of previous pulmonary arterial hypertension trials.
Langleben D; Brock T; Dixon R; Barst R;
J Cardiovasc Pharmacol; 2004 Nov; 44 Suppl 1():S80-4. PubMed ID: 15838366
[TBL] [Abstract][Full Text] [Related]
18. Ambrisentan: a review of its use in pulmonary arterial hypertension.
Rivera-Lebron BN; Risbano MG
Ther Adv Respir Dis; 2017 Jun; 11(6):233-244. PubMed ID: 28425346
[TBL] [Abstract][Full Text] [Related]
19. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
Chen YJ; Li LJ; Tang WL; Song JY; Qiu R; Li Q; Xue H; Wright JM
Cochrane Database Syst Rev; 2018 Nov; 11(11):CD008170. PubMed ID: 30480768
[TBL] [Abstract][Full Text] [Related]
20. An evidence-based approach to the management of pulmonary arterial hypertension.
Archer SL; Michelakis ED
Curr Opin Cardiol; 2006 Jul; 21(4):385-92. PubMed ID: 16755209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
